Autoimmune therapy is any medical treatment designed to calm or reset an immune system that has begun attacking the body’s own tissues. Because autoimmune diseases range from rheumatoid arthritis to lupus to multiple sclerosis, there is no single therapy. Instead, doctors draw from a toolkit that includes broad immunosuppressants, targeted biologic drugs, newer small-molecule pills, and, most recently, cell-based therapies borrowed from cancer medicine. The goal across all of them is the same: reduce inflammation, prevent organ damage, and ideally push the disease into remission.
How Autoimmune Therapy Works
In a healthy immune system, white blood cells learn to distinguish the body’s own tissues from genuine threats like bacteria or viruses. In autoimmune disease, that distinction breaks down. Certain immune cells begin producing antibodies against joints, skin, kidneys, or other organs, triggering chronic inflammation. Every class of autoimmune therapy intervenes somewhere along this chain, either by suppressing immune cells broadly or by blocking specific chemical signals that drive the attack.
The simplest way to think about the options is in three tiers. Traditional immunosuppressants turn down the entire immune system. Biologic drugs target one precise molecule or cell type in the inflammatory cascade. And the newest approaches, like CAR-T cell therapy, attempt to selectively eliminate the rogue immune cells responsible for the disease while leaving the rest of the immune system largely intact.
Traditional Immunosuppressants
Corticosteroids are usually the first line of defense during a flare. They work fast, dampening inflammation within hours to days, but they carry well-known side effects when used long term: weight gain, bone thinning, elevated blood sugar, and mood changes. Most treatment plans aim to taper steroids as quickly as possible and rely on other drugs to maintain control.
Those maintenance drugs include medications that slow the growth of immune cells. Some block enzymes that immune cells need to multiply. Others interfere with the chemical signals between immune cells, preventing them from organizing a sustained attack. These medications take weeks or months to reach full effect, which is why steroids often bridge the gap early on. The tradeoff is that by broadly suppressing immune function, these drugs raise your vulnerability to infections. In one study of patients on immunosuppressive regimens, nearly 30% developed a bacterial infection during follow-up, though the majority were minor (skin or urinary infections) rather than serious. About 5% required hospitalization, most commonly for pneumonia.
Biologic Drugs
Biologics represented a major leap forward because they zero in on specific molecules instead of suppressing the whole immune system. The most widely used class targets a protein called TNF-alpha, one of the earliest alarm signals the immune system sends when it detects a threat. In autoimmune disease, TNF-alpha is produced in excess, fueling ongoing inflammation. TNF-blocking drugs, first approved in 1998, bind to this protein and neutralize it. Some can also recruit the body’s own complement system to destroy the cells producing TNF.
Another class blocks a signaling molecule called IL-6, which plays an outsized role in rheumatoid arthritis. IL-6 doesn’t just trigger inflammation directly. It also reprograms helper T cells, stimulates the bone-eroding cells called osteoclasts, and activates B cells that produce harmful antibodies. Elevated IL-6 is consistently found in the joint fluid of people with RA, and drugs that block its receptor have proven effective in large clinical trials.
A third biologic strategy is B-cell depletion. B cells are the immune cells that manufacture antibodies, including the self-targeting antibodies that drive diseases like lupus. By selectively wiping out B cells, these therapies remove the source of those harmful antibodies. B cells eventually regenerate, but in many patients the new crop doesn’t resume the autoimmune attack, at least for a period of months to years.
Small-Molecule Targeted Therapies
JAK inhibitors are oral pills that block a family of enzymes called Janus kinases, which relay inflammatory signals inside immune cells. Unlike biologics, which are large protein molecules that must be injected or infused, JAK inhibitors are small enough to be taken as a daily tablet. They are currently approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and certain forms of childhood arthritis.
The convenience of a pill comes with specific safety considerations. The FDA requires warnings on JAK inhibitors about increased risks of serious heart-related events, certain cancers, and blood clots. These risks appear most relevant in older adults and people with existing cardiovascular risk factors, so doctors weigh them carefully when choosing between a JAK inhibitor and a biologic.
CAR-T Cell Therapy
The most dramatic recent development borrows a technique from cancer treatment. CAR-T cell therapy involves drawing a patient’s own immune cells, engineering them in a laboratory to target B cells, and infusing them back into the body. The engineered cells hunt down and destroy B cells far more thoroughly than conventional B-cell-depleting drugs.
A case series published in the New England Journal of Medicine followed 15 patients with severe, treatment-resistant lupus, inflammatory muscle disease, or systemic sclerosis who received a single infusion. The results were striking: all eight lupus patients achieved full remission, with their disease-driving antibodies disappearing and remaining negative for up to 29 months. All three patients with inflammatory muscle disease had a major clinical response, and all four with systemic sclerosis saw their disease activity scores drop. Every patient in the study was able to stop all other immunosuppressive medications entirely.
Side effects were mostly mild. Ten of the 15 patients developed low-grade cytokine release syndrome, a temporary flu-like reaction as the engineered cells activate. One patient was hospitalized for pneumonia. B cells were depleted for an average of about four months before regenerating, and when they returned, the autoimmune attack did not resume during follow-up. This approach is still limited to specialized centers and severe cases, but it represents the closest thing to a potential cure that autoimmune medicine has seen.
What Treatment Looks Like Day to Day
How you receive autoimmune therapy depends on the drug. Traditional immunosuppressants and JAK inhibitors are pills taken daily at home. Some biologics come as pre-filled syringes or auto-injectors that you learn to self-administer under the skin, typically weekly or every two weeks. Others require intravenous infusion at a clinic or hospital, scheduled every few weeks to every few months.
When given the choice, most patients prefer treating at home. A meta-analysis of studies comparing home injection to hospital infusion found that 84% of patients preferred the home setting, largely because it eliminates travel time and disruption to daily routines. The initial learning curve for self-injection is short: most people feel comfortable after one or two training sessions with a nurse.
What Remission Actually Means
The word “remission” in autoimmune disease doesn’t always mean what people hope. Doctors use a spectrum of targets. The most achievable is clinical remission on treatment, meaning your symptoms and lab markers are quiet but you’re still taking medication. The most ambitious is complete remission: no symptoms, normal bloodwork (including antibody levels and immune markers returning to normal range), no steroids, and no immunosuppressive drugs. Most patients land somewhere in between, in a state called low disease activity, where symptoms are minimal and organ damage is not progressing.
Treatment plans are adjusted over time to push toward the best target a given patient can sustain. Even low disease activity, short of full remission, significantly reduces the risk of long-term organ damage and improves quality of life.
Lifestyle Factors That Affect Outcomes
Medical therapy works better when certain lifestyle factors are addressed alongside it. Smoking is one of the clearest modifiable risks: it worsens joint damage in rheumatoid arthritis, reduces how well medications work, and accelerates blood vessel complications. In inflammatory muscle disease, smoking and heavy alcohol use are linked to higher rates of specific harmful antibodies.
Diet appears to matter as well. A large observational study of over 200,000 women found that high intake of ultra-processed foods was associated with a 56% increased risk of lupus. Conversely, following a Mediterranean-style diet (rich in fruits, vegetables, whole grains, and healthy fats) has been linked to lower disease activity scores in RA patients. The benefit may partly work through the gut: people with RA who closely followed a Mediterranean diet showed shifts in their gut bacteria, with decreases in species linked to inflammation and increases in species known to promote regulatory immune cells that help suppress autoimmunity.
Exercise is safe and beneficial even in inflammatory muscle diseases, where patients and doctors once feared it would worsen muscle damage. Studies show that structured exercise programs reduce inflammation markers without elevating the enzymes that signal muscle breakdown. Stress management also plays a measurable role: daily stress was strongly associated with symptom flares in 74% of patients surveyed, and techniques like mindfulness and cognitive behavioral therapy have shown the ability to reduce stress-driven inflammation.
People who score well on a composite healthy lifestyle index, combining moderate alcohol use, healthy weight, not smoking, a balanced diet, and regular exercise, have a 58% lower risk of developing lupus in the first place, with even greater protection against the most antibody-driven forms of the disease.